Andrea Torres is an Endocrinology/Metabolic physician. OpenAlex indexes 64 publications with 2,729 citations (h-index 19).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
13333 Dotson Rd Ste 220
Houston, TX 770704305
Telephone
281-251-5234Provider last certified this registry record 27 Nov 2025.
Industry payments
55 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novo Nordisk IncProgram year202516 payments
- Lilly USA, LLCProgram year202511 payments
- Amgen Inc.Program year202513 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
56.4%GLP-1 receptor agonist18%Ozempic70%Mounjaro17%Trulicity7%Rybelsus5%Part D<11 patientsInsulin Analog12.5%Lantus Solostar19%Humalog Kwikpen U-10012%Tresiba Flextouch U-20012%Tresiba Flextouch U-10011%Humalog Kwikpen U-2008%Novolog8%Insulin Lispro Kwikpen U-1007%Toujeo Solostar6%Fiasp6%Novolog Flexpen5%Humalog4%Tresiba4%Part D<11 patients+ 7 more classes in this area
Cardiovascular
26.5%Statin12.5%Rosuvastatin Calcium47%Atorvastatin Calcium41%Simvastatin7%Pravastatin Sodium5%Part D<11 patientsACE inhibitor3.6%Lisinopril70%Lisinopril-Hydrochlorothiazide30%Part D<11 patients+ 7 more classes in this area
Hormonal (systemic)
14.3%l-Thyroxine12.1%Levothyroxine Sodium56%Synthroid30%Unithroid15%Part D≥57 patientsThyroid Hormone Synthesis Inhibitor1.2%Methimazole100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Effects of icosapent ethyl according to baseline residual risk in patients with atherosclerotic cardiovascular disease: results from REDUCE-IT
European Heart Journal - Cardiovascular Pharmacotherapy
2024 - Postconception age at surgery as a predictor of ventriculoperitoneal shunt failure
Journal of Neurosurgery Pediatrics
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Bruce Bartholow Duncan
Universidade Federal do Rio Grande do Sul
Alireza Esteghamati
Tehran University of Medical Sciences
Paul Zimmet
Monash University
André Pascal Kengne
South African Medical Research Council
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”